Abstract
Carcinoembryonic antigen (CEA) elimination kinetics after tumor resection were measured in a case of breast cancer. A 45-year-old woman with a left breast carcinoma underwent surgery after neoadjuvant chemotherapy. The serum CEA level before surgery was 34.3 ng/ml. After sequential monitoring of serum CEA levels, postoperative serum CEA elimination kinetics were calculated using non-linear least square analysis with the fitting equation C(t) = (CO — Cp)exp(-kt) + Cp, where C(t) was the postoperative CEA level, t was the number days after surgery, CO was the CEA level at postoperative time zero, Cp was the CEA at plateau, and k was the rate constant of elimination.
Cp was calculated as 6.9 ng/ml, which was above the cut-off level and indicated residual malignancy. After adjuvant chemotherapy, CEA normalized to 1.8 ng/ml. In breast cancer patients with high preoperative serum CEA levels, our analytical method for CEA elimination might be useful for the detection of residual malignancies.
Abbreviations
- CEA:
-
Carcinoembryonic antigen
- Cp:
-
Postoperative serum CEA level at plateau
- Pp:
-
Postoperative CEA production
References
See WA, Cohen MB, Hoxie LD: Alpha-Fetoprotein half-life as a predictor of residual testicular tumor.Cancer 71:2048–2054,1993.
Pontes JE, Jabalameli P, Montie J, Foemmel R, Howard PD, Boyett J: Prognostic implications of disappearance rate of biologic markers following radical prostatectomy.Urology 36:415–419,1990.
Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, Brendler CB, Walsh PC: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.J Urol 139:766–772, 1988.
van Straalen JP, Bossens MM, de Reijke TM, Sanders GT: Biological half-life of prostate-specific antigen after radical prostatectomy.Eur J Clin Chem Clin Biochem 32:53–55,1994.
Verhelst J, Van den Broecke E, Van Meerbeeck J, De Backer W, Blockx P, Vermeire P: Calculation of half-life of carcinoembryonic antigen after lung tumour resection: a case report.Eur Respir J 4:374–376,1991.
Yoshimasu T, Miyoshi S, Maebeya S, Suzuma T, Bessho T, Hirai I, Tanino H, Arimoto J, Naito Y: Analysis of the early postoperative serum carcinoembryonic antigen time-course as a prognostic tool for bronchogenic carcinoma.Cancer 79:1533–1540,1997.
Yoshimasu T, Maebeya S, Suzuma T, Bessho T, Taino H, Arimoto J, Naito Y: Prediction of the lung cancer recurrence by the analysis of CEA disappearance curve after surgery.J Jpn Soc Molecular Tumor Marker Res (in Japanese) 13:131–133,1998.
Legare RD, Strenger R: Adjuvant therapy in breast cancer.Obstet Gynecol Clin North Am 29:201–208, 2002.
Mincey BA, Palmieri FM, Perez EA: Adjuvant therapy for breast cancer: recommendations for management based on consensus review and recent clinical trials.Oncologist 7:246–250, 2002.
Taguchi T: Meeting highlights-International Consensus Panel on the treatment of primary breast cancer.Jpn J Cancer Chemother 29:347–363,2002.
Thuerlimann B: International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland.Breast Cancer 8:294–297, 2001.
Yoshimasu T, Maebeya S, Suzuma T, Bessho T, Tanino H, Arimoto J, Sakurai T, Naito Y: Disappearance curves for tumor markers after resection of intrathoracic malignancies.Int J Biol Markers 14:99–105,1999.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yoshimasu, T., Sasaki, R., Oura, S. et al. A case of serum CEA disappearance curve after resection of breast carcinoma. Breast Cancer 11, 203–205 (2004). https://doi.org/10.1007/BF02968302
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02968302